University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program

The University of Szeged reports over 70 robotic arrhythmia procedures in just over a month using Stereotaxis’ Genesis system, a record early usage pace.

Rhea-AI Summary

Stereotaxis (STXS)/b) announced that the University of Szeged in Hungary has treated over 70 arrhythmia patients with the Genesis Robotic Magnetic Navigation system just over one month after launching its robotic cardiology program in July.The Electrophysiology team at the Szent-Györgyi Albert Clinical Center, led by Prof. Tamás Szili-Török, has used the system for a broad range of arrhythmias, including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia. Early cases included complex single arm-access procedures and treatments of patients with multiple previous failed ablations that the hospital states were not successfully treatable without robotics. The University of Szeged is the first hospital in Hungary with a robotic cardiology program and plans to celebrate the grand opening at a scientific symposium on September 8.

Positive

• Over 70 patients treated robotically just over one month after program launch, described as outpacing any previous Genesis system launch
• First robotic cardiology program in Hungary established at the University of Szeged using Stereotaxis’ Genesis system
• Robotics used to treat multiple complex arrhythmias, including cases with several previously failed ablation procedures

Negative

• None.

Market Context

STXS had a pre-publication 0.73% gain, while the current scanner recorded NYXH at 11.92052960395813%...

Analysis

STXS had a pre-publication 0.73% gain, while the current scanner recorded NYXH at 11.92052960395813% higher. That limited peer participation frames the program update as company-specific context; the active S-3 resale registration remains a disclosed dilution consideration.

Key Figures

Patients treated: over 70 patients System installation: July Symposium date: September 8th +2 more

5 metrics

Patients treated over 70 patients just over a month after program launch

System installation July University of Szeged installation

Symposium date September 8th upcoming scientific symposium

Arrhythmia prevalence tens of millions of individuals worldwide

Patients treated globally over 150,000 patients Stereotaxis technology history

Historical Context

5 past events · Latest: Aug 11 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 11	Earnings report	Negative	-4.7%	Revenue declined and net loss increased from the prior-year quarter.
Aug 03	Board appointment	Positive	+6.8%	Myriam Curet joined the board as an independent director.
Jul 21	Earnings scheduling	Neutral	-2.0%	The company scheduled its second-quarter results release and conference call.
Jul 20	Program launch	Positive	-3.2%	Hungary's first robotic cardiology program launched at the University of Szeged.
Jul 09	Acquisition completion	Positive	-3.3%	Stereotaxis completed its acquisition of Robocath.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

STXS's prior positive operational and transaction announcements were followed by declines, while the latest earnings report also fell.

Key Terms

electrophysiology, arrhythmia, atrial fibrillation, cardiac ablation

4 terms

electrophysiology medical

"the Electrophysiology team at the University of Szeged in Hungary"

The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

arrhythmia medical

"successfully treated over 70 patients using the Genesis system"

An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.

atrial fibrillation medical

"patients with paroxysmal and persistent atrial fibrillation"

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

cardiac ablation medical

"to cardiac ablation, a common minimally invasive procedure"

Cardiac ablation is a medical procedure that uses heat, cold, or energy to destroy small areas of heart tissue that cause abnormal electrical signals and irregular heartbeats. For investors, it matters because the procedure drives demand for specialized medical devices, hospital services, and ongoing treatment revenues, and changes in its safety, effectiveness, or insurance coverage can materially affect companies and clinical adoption—think of it as targeted surgery that resets a misfiring circuit in the heart.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in July
• Over 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globally
• Robotics enabled successful treatment of patients with multiple previously failed ablation procedures
• University of Szeged to celebrate leadership in technology and grand opening of Robotic Cardiology Program at upcoming scientific symposium on September 8^th

ST. LOUIS, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the Electrophysiology team at the University of Szeged in Hungary has successfully treated over 70 patients using the Genesis Robotic Magnetic Navigation system, just over a month after launching its robotic cardiology program.

Since the official lab opening, the Electrophysiology team at the Cardiology Center (Szent-Györgyi Albert Clinical Center) at the University of Szeged, led by Prof. Tamás Szili-Török, has used the Genesis robotic system to treat a broad spectrum of arrhythmia patients. These include patients with paroxysmal and persistent atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia. Among the first procedures performed by the team included several complex and innovative procedures, including several arm-access procedures using a single-access catheter from various alternative access sites, and the treatment of patients with multiple previous failed procedures who could not successfully be treated without robotics.

“Our new Genesis robotic program has had a very successful start and is an important cornerstone in our strategy to provide the most advanced treatment options for our patients.” said Prof. Tamás Szili-Török, Vice Dean of Science and Innovation and Director of Cardiology Center at the University of Szeged. “Treating over seventy patients in our first month is an exciting achievement and reflects both the dedication of our team and the need for advanced arrhythmia care in our community. We look forward to continuing to lead the community in advancing the frontiers of robotic care, technology, and science.”

The University of Szeged is the first hospital in Hungary to establish a robotic cardiology program. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“The quantity and quality of robotic arrhythmia care provided by the University of Szeged in such a rapid period is a remarkable achievement outpacing any previous launch of our technology,” said David Fischel, Chairman and CEO of Stereotaxis. “We congratulate the Szeged team and look forward to continuing to work together to advance impactful innovation, research, and patient care.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

What did Stereotaxis (STXS) announce about the University of Szeged’s robotic cardiology program?

Stereotaxis announced that the University of Szeged’s Electrophysiology team has treated over 70 arrhythmia patients using the Genesis Robotic Magnetic Navigation system just over one month after launching its robotic cardiology program.

How many patients have been treated with Stereotaxis’ Genesis system at the University of Szeged?

The University of Szeged has treated over 70 patients with the Genesis Robotic Magnetic Navigation system in just over a month, a usage pace the company describes as outpacing any previous launch of its technology.

What types of arrhythmias are being treated robotically at the University of Szeged with STXS technology?

The Genesis system at the University of Szeged has been used for a broad spectrum of arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia.

What makes the University of Szeged’s robotic cardiology program notable for Stereotaxis (STXS)?

The University of Szeged is the first hospital in Hungary to establish a robotic cardiology program and, according to Stereotaxis, has achieved a record early usage pace, including complex procedures and patients with multiple previously failed ablations.

When will the University of Szeged officially celebrate its Robotic Cardiology Program using Stereotaxis’ Genesis system?

The University of Szeged plans to celebrate its leadership in technology and the grand opening of its Robotic Cardiology Program on September 8 at an upcoming scientific symposium.